Exane Derivatives raised its position in shares of Zoetis Inc (NYSE:ZTS) by 54.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 15,045 shares of the company’s stock after purchasing an additional 5,330 shares during the period. Exane Derivatives’ holdings in Zoetis were worth $1,874,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of ZTS. Huntington National Bank raised its position in shares of Zoetis by 3.0% during the second quarter. Huntington National Bank now owns 2,975 shares of the company’s stock valued at $338,000 after buying an additional 87 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC raised its position in shares of Zoetis by 1.8% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 4,980 shares of the company’s stock valued at $565,000 after buying an additional 89 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its position in shares of Zoetis by 0.6% during the second quarter. Vestmark Advisory Solutions Inc. now owns 15,106 shares of the company’s stock valued at $1,714,000 after buying an additional 89 shares during the last quarter. Intellectus Partners LLC raised its position in shares of Zoetis by 1.1% during the second quarter. Intellectus Partners LLC now owns 8,040 shares of the company’s stock valued at $912,000 after buying an additional 91 shares during the last quarter. Finally, Rehmann Capital Advisory Group raised its position in shares of Zoetis by 4.0% during the first quarter. Rehmann Capital Advisory Group now owns 2,550 shares of the company’s stock valued at $257,000 after buying an additional 97 shares during the last quarter. 90.11% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have recently issued reports on ZTS. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $111.00 to $120.00 in a research report on Monday, July 1st. They noted that the move was a valuation call. Morgan Stanley lifted their price objective on shares of Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research report on Monday, September 30th. Goldman Sachs Group initiated coverage on shares of Zoetis in a research report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price target on the stock. Craig Hallum boosted their price target on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Argus set a $140.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $123.69.
ZTS stock traded up $2.15 during mid-day trading on Tuesday, reaching $128.74. 1,637,961 shares of the stock traded hands, compared to its average volume of 1,781,518. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. Zoetis Inc has a one year low of $78.90 and a one year high of $130.09. The stock has a market capitalization of $61.35 billion, a PE ratio of 41.13, a PEG ratio of 3.18 and a beta of 0.87. The business has a 50-day moving average price of $125.38 and a two-hundred day moving average price of $113.45.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.51 billion. During the same quarter in the previous year, the business posted $0.77 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Monday, October 21st. Zoetis’s dividend payout ratio is currently 21.09%.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: What is channel trading?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.